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Introduction {#sec005}
============

Colorectal cancer (CRC) is the third most common cancer in men, the second most common cancer in women, and the fourth most common cause of cancer-related deaths worldwide \[[@pone.0220579.ref001]\]. Curative resection is the gold-standard treatment for non-metastatic CRC. However, despite the advances in the preceding decades, CRC survival remains unsatisfactory. Therefore, it is critically important to optimize the treatment, including the use of adjuvant therapies, for curatively resectable disease by identifying patients at greater risk for worse outcomes. Pathologic stage is the most important prognostic indicator for CRC; however, recently, there had been increasing interest in improving CRC prognostication using routine blood test data. Although there had been many studies that investigated several biomarkers, the results were inconsistent \[[@pone.0220579.ref002]--[@pone.0220579.ref015]\]. Notably, biomarkers that are reliable and easy to obtain are required to implement adequate relapse risk and survival assessments. Therefore, the aim of the present study is to identify blood cell markers that can prognosticate the long-term outcomes of CRC patients, independent of tumor stage.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

We reviewed a prospectively recorded database of stage II and III CRC patients who underwent elective R0 resection at the Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, between January 2003 and December 2013. Patients who underwent chemotherapy or radiotherapy before surgery or those who underwent R1 or R2 resection were excluded. A total of 892 patients were identified and included in the study. The mean patient age was 68.6 ± 10.3 years (range, 19--93 years), and 57.3% were men. In accordance with the Japanese Society for Cancer of the Colon and Rectum guidelines \[[@pone.0220579.ref016]\], postoperative adjuvant chemotherapy (PAC) was administered for stage III patients and stage II patients at high risk for recurrence (i.e., T4, perforation, poorly differentiated adenocarcinoma, vascular invasion, and bowel obstruction), with informed consent. After exclusion of patients who refused, 39 (9%) stage II and 232 (52%) stage III patients received PAC. The most frequently used PAC regimens were uracil/ tegafur and oral leucovorin, uracil/ tegafur, XELOX, capecitabine, and S-1.

Methods {#sec008}
-------

The preoperative routine blood test data obtained within 2 weeks before surgery included white blood cell count, neutrophils (%), lymphocytes (%), monocytes (%), red blood cell (RBC) count, hemoglobin concentration (Hb), mean corpuscular volume (MCV), red cell distribution width (RDW), platelet count, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to- monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR). In addition, C-reactive protein (CRP), serum albumin, total cholesterol (T-Chol), Glasgow prognostic score (GPS), controlling nutritional status (CONUT) score, and Onodera's prognostic nutrition index (PNI) were investigated as the conventional prognostic scores that reflected systemic inflammatory, nutritional, and immunologic status \[[@pone.0220579.ref007], [@pone.0220579.ref014], [@pone.0220579.ref015]\]. The GPS comprised high CRP level (\>1.0 mg/dL) and hypoalbuminemia (\<3.5 g/dL); patients with both criteria were allocated a score of 2, those with only 1 criterion were allocated a score of 1, and those without abnormalities were allocated a score of 0 \[[@pone.0220579.ref007]\]. PNI was calculated as follows: 10 × albumin value (g/dL) + 0.005 × lymphocyte of the peripheral blood. A higher value suggested good immune-nutritional status \[[@pone.0220579.ref014]\]. CONUT score was calculated from three parameters, serum albumin, T-Chol, and total peripheral lymphocyte count; a lower value indicated favorable nutritional status \[[@pone.0220579.ref015]\]. The cutoff values of the continuous variables were determined by receiver operating characteristic (ROC) curve analysis for discriminating relapse/non-relapse in patients who were followed up for more than 3 years. In the ROC analysis, the optimal cutoff values were determined to be the point where the vertical distance between the ROC curve and the diagonal line was maximal.

The resected CRCs were histopathologically classified according to the seventh edition of the UICC/TNM classification \[[@pone.0220579.ref017]\]. Our surgical department followed a standardized surveillance protocol, wherein patients were followed up by clinical assessment every 3 months for 5 years. The collected postoperative data included clinical assessments, laboratory tests, and computed tomography of the chest, abdomen, and pelvis. All evidences of disease recurrence were obtained from the patients' medical records. The disease relapse was determined by imaging modalities including CT and FDG-PET, physical findings and blood tests including serum CEA and CA19-9. Follow-up information through July 2017 was compiled for all survivors. The RFS was calculated based on the time from the date of surgery to the date of identification of disease relapse, whereas the overall survival (OS) was based on the duration from surgery to death due to any cause.

We attempted to identify the prognostic factors from the blood data and the previously reported prognostic scores that had a significant relationship with RFS and OS using univariate and multivariate analyses. The study protocol was approved by the Ethics Review Committee of Japanese Red Cross Nagoya First Hospital (approval number: 2018--080), which waived the need for informed consent due to the retrospective nature of the study.

Statistical analysis {#sec009}
--------------------

Continuous variables were expressed as mean ± SD or median, IQR, and were compared using student t-test. Differences in categorical variables were compared using chi-square test. The Kaplan--Meier method was used to estimate survival curves, whereas the log-rank test was employed to evaluate the differences in survival between groups. Considering the statistical significance and clinical implications of the univariate analysis, variables were entered into a multivariate analysis to identify the significant independent prognostic factors of RFS and OS. The neutrophil (%), lymphocyte (%), and NL R were integrated into NLR, because they had a close relationship, and the AUC of the NLR was larger than that of neutrophil (%) and lymphocyte (%). Similarly, RBC count and Hb were integrated into Hb. Hazard ratio (HR) and 95% confidence interval (CI) were calculated during multivariate analysis using a Cox proportional hazard model. To develop an easy scoring system for RFS, a laboratory prognostic score (LPS) was calculated based on the log of the regression coefficient of the factors \[[@pone.0220579.ref018]\]. According to the method described by Moons KG \[[@pone.0220579.ref018]\], the natural logarithm of the hazard ratio in Cox proportional hazard model (the regression coefficients) was multiplied by 10, and rounded to the nearest integer to obtain easily applicable scores per predictor. An MCV ≥ 80.5 fL, NLR ≥ 5.5, and LMR \< 3.4 were scored 3, 2, and 1, respectively. Statistical analyses were performed using JMP version 10.0 for Windows (SAS Institute Inc., Cary, NC, USA) at a significance level of p \< 0.05.

Results {#sec010}
=======

The patient demographics are presented in [Table 1](#pone.0220579.t001){ref-type="table"}. Five patients died from postoperative complications (operative mortality rate = 0.56%). The median follow-up duration was 58.7 months (interquartile range, 28.2--86.9 months).

10.1371/journal.pone.0220579.t001

###### Patients demographics.

![](pone.0220579.t001){#pone.0220579.t001g}

  ------------------------------------- ---------------------------------------- ------------------- ---- ----------------
  Age                                                                            68.6±10.3                
  Sex (M:F)                                                                      511:381                  
  Tumor location                                                                                          
                                        Cecum                                    69                       (8%)
                                        Appendix                                 7                        (1%)
                                        Ascending colon                          145                      (16%)
                                        Transverse colon                         96                       (11%)
                                        Descending colon                         58                       (7%)
                                        Sigmoid colon                            241                      (27%)
                                        Rectum                                   271                      (30%)
  Histological grade                                                                                      
                                        well differentiated                      59                       (7%)
                                        moderately differentiated                766                      (86%)
                                        poorly differentiated                    12                       (1%)
                                        other                                    55                       (6%)
  T                                                                                                       
                                        1                                        13                       (2%)
                                        2                                        47                       (5%)
                                        3                                        690                      (77%)
                                        4                                        142                      (16%)
  N                                                                                                       
                                        0                                        448                      (50%)
                                        1                                        324                      (36%)
                                        2                                        102                      (11%)
  Stage                                                                                                   
                                        II                                       448                      (50%)
                                        III                                      444                      (50%)
  Preoperative laboratory data                                                                            
                                        C-reactive protein (mg/dL)               1.15±2.42                (0--24.7)
                                        Albumin (g/dL)                           3.75±0.6                 (1.2--4.9)
                                        Total cholesterol (mg/dL)                176.1±41.8               (65.0--410.0)
                                        White blood cell count (x10^9^/L)        6.45±2.21                (1.9--19.5)
                                        Neutrophil (%)                           63.9 (56.8--71.2)        (20.1--96.9)
                                        Lymphocyte (%)                           25.1±9.1                 (1.9--69.4)
                                        Monocyte (%)                             7.8±2.7                  (1.1--29.3)
                                        Red blood cell count (x10^9^/μL)         3.98 (3.61--4.34)        (2.09--6.00)
                                        Hemoglobin (g/dL)                        11.6±2.0                 (5.8--17.5)
                                        Mean corpuscular volume (MCV)(fl)        88.2±8.5                 (59.2--118.5)
                                        Red cell distribution width (RDW)        16.9±5.5                 (0--39.6)
                                        Platelets count (x10^9^/L)               275.8±101.8              (39.0--1221.0)
                                        Neutrophil-to-lymphocyte ratio (NLR)     3.25±2.80                (0.34--51.0)
                                        Lymphocyte-to-monocyte ratio (LMR)       3.58±2.58                (0.54--63.09)
                                        Platelets-to-lymphocyte ratio (PLR)      210.62±153.47            (31.0--2284.0)
                                        Glasgow prognostic score (GPS)           0.556±0.748              (0--2)
                                        Controlling nutritional status (CONUT)   2.49±2.35                (0--12)
                                        Onodera PNI                              45.17±6.95               (14.9--67.9)
  Postoperative adjuvant chemotherapy                                                                     
                                        done                                     137                      (15%)
                                        -Stage II                                37                       (4%)
                                        -Stage III                               100                      (11%)
  　                                    not done                                 749                 　   (85%)
  ------------------------------------- ---------------------------------------- ------------------- ---- ----------------

The 5-year RFS rates of patients with stage II and III CRC were 83.8% and 62.7%, respectively. Univariate analysis showed that tumor location, stage, PAC, neutrophil (%), lymphocyte (%), RBC count, Hb, MCV, RDW, platelet count, NLR, and LMR were significantly correlated with RFS ([Table 2](#pone.0220579.t002){ref-type="table"}). Subsequent multivariate analysis showed that tumor location, stage, MCV, NLR, and LMR were significantly correlated with RFS. An MCV ≥ 80.5 fL, NLR ≥ 5.5, and LMR \< 3.4 had HRs for disease relapse between 1.39 and 1.93. The proportion of MCV\<80.5 fL in patients with right sided CRC (RCRC) and left sided CRC (LCRC) were 24.3% and 14.4%, respectively (p = 0.0002, [Table 3](#pone.0220579.t003){ref-type="table"}). On the other hand, LMR was significantly lower in RCRC than in LCRC (3.08 vs. 3.44, p = 0.0040, [Table 3](#pone.0220579.t003){ref-type="table"}). A subgroups analysis of the tumor location showed that MCV was remained as a prognostic factor: Five year RFS of patients with MCV\<80.5 fL and ≧80.5 fL were 87.3% and 73.6%, respectively (p = 0.0147) in RCRC, while those were 85.7% and 68.9%, respectively (p = 0.0027) in LCRC. The prognostic values of CRP, albumin, T-Chol, GPS, CONUT score, and Onodera's PNI were not significantly correlated with RFS.

10.1371/journal.pone.0220579.t002

###### Univariate and multivariate analyses of clinical and pathological parameters for the prediction of relapse-free survival.
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                                                                                                Univariate analysis   Multivariate analysis                            
  ------------------------------------- ---------------------------------------- -------- ----- --------------------- ------------------------ ----------------------- --------------
  Age                                   \<65                                              271   73.2%                 0.8905                                           
                                        ≧65                                               621   73.4%                                                                  
  Sex                                   Male                                              511   71.4%                 0.2319                                           
                                        Female                                            381   75.9%                                                                  
  Tumor location                        Right sided colon                                 317   77%                   **0.0010**               1.11 (0.78--1.58)       0.5414
                                        Left side colon                                   299   76.6%                 1                                                
                                        Rectum                                            276   65.4%                 **1.55 (1.12--2.143)**   **0.0073**              
  Histological grade                    well differentiated                               59    72.9%                 0.9345                                           
                                        moderately differentiated                         766   73.5%                                                                  
                                        poorly differentiated                             12    73.3%                                                                  
                                        other                                             55    71.0%                                                                  
  Stage                                 II                                                448   83.8%                 **\<0.0001**             1                       **\<0.0001**
                                        III                                               444   62.7%                 **2.66 (1.93--3.68)**                            
  Laboratory Data                       C-reactive protein (mg/dL)               \<0.5    424   74.3%                 0.0814                                           
                                                                                 ≧0.5     249   68.6%                                                                  
                                        Albumin (g/dL)                           \<2.7    36    62.0%                 0.4339                                           
                                                                                 ≧2.7     856   73.6%                                                                  
                                        Total cholesterol (mg/dL)                \<220    758   72.7%                 0.2932                                           
                                                                                 ≧220     134   76.6%                                                                  
                                        White blood cell count (x10^9^/L)        \<5.50   325   77.0%                 0.1442                                           
                                                                                 ≧5.50    567   71.2%                                                                  
                                        Neutrophil (%)                           \<73.7   751   74.6%                 **0.0460**                                       
                                                                                 ≧73.7    141   66.5%                                                                  
                                        Lymphocyte (%)                           \<14.9   111   65.9%                 **0.0412**                                       
                                                                                 ≧14.9    781   74.4%                                                                  
                                        Monocyte (%)                             \<8.0    540   75.8%                 **0.0446**                                       
                                                                                 ≧8.0     352   69.3%                                                                  
                                        Red blood cell count (x10^9^/μL)         \<3.53   187   66.2%                 **0.0093**                                       
                                                                                 ≧3.53    705   75.0%                                                                  
                                        Hemoglobin (g/dL)                        \<9.5    154   84.3%                 **0.0026**               1                       0.1562
                                                                                 ≧9.5     738   71.3%                 1.42 (0.87--2.41)                                
                                        Mean corpuscular volume (MCV) (fl)       \<80.5   160   86.2%                 **\<0.0001**             1                       **0.0082**
                                                                                 ≧80.5    732   70.4%                 **1.93 (1.17--3.32)**                            
                                        Red cell distribution width (RDW)        \<18.5   680   71.0%                 **0.0058**               1.13 (0.77--1.73)       0.5264
                                                                                 ≧18.5    212   80.9%                 1                                                
                                        Platelets count (x10^9^/L)               \<364    746   71.6%                 **0.0105**                                       
                                                                                 ≧364     146   82.2%                                                                  
                                        Neutrophil-to-lymphocyte ratio (NLR)     \<5.5    801   74.5%                 **0.0098**               1                       **0.0239**
                                                                                 ≧5.5     91    62.7%                 **1.62 (1.07--2.40)**                            
                                        Lymphocyte-to- monocyte ratio (LMR)      \<3.4    466   70.4%                 **0.0234**               **1.39 (1.05--1.86)**   **0.0231**
                                                                                 ≧3.4     426   76.4%                 1                                                
                                        Platelets-to-lymphocyte ratio (PLR)      \<218    607   74.6%                 0.1954                                           
                                                                                 ≧218     285   70.6%                                                                  
                                        Glasgow prognostic score (GPS)           0        404   72.0%                 0.9171                                           
                                                                                 1--2     269   72.8%                                                                  
                                        Controlling nutritional status (CONUT)   0--4     741   73.4%                 0.3973                                           
                                                                                 5--12    151   73.1%                                                                  
                                        Onodera PNI                              \<41.8   252   72.5%                 0.3176                                           
                                                                                 ≧41.8    640   73.7%                                                                  
  Postoperative adjuvant chemotherapy   done                                              271   66.1%                 **0.0020**               0.95 (0.0--1.28)        0.7293
                                        not done                                          621   76.7%                 1                                                

10.1371/journal.pone.0220579.t003

###### Relations between MCV, NLR, LMR and tumor location.

MCV was significantly smaller in right sided CRC than in left sided CRC, while LMR was significantly lower in the right sided CRC than the left sided CRC.

![](pone.0220579.t003){#pone.0220579.t003g}

                        Right CRC (n = 317)   Left CRC (n = 575)   P
  --------- ----------- --------------------- -------------------- --------------
  **MCV**   Median      86.4±8.7              89.2±8.2             **\<0.0001**
            \<80.5 fL   77 (24.3%)            83 (14.4%)           **0.0002**
            ≧80.5 fL    240 (75.7%)           492 (85.6%)          
  **NLR**   Median      3.27±2.22             3.23±3.07            0.1170
            \<5.5       283 (89.3%)           518 (90.1%)          0.7012
            ≧5.5        34 (10.7%)            57 (9.9%)            
  **LMR**   Median      3.51±3.70             3.62±1.68            **0.0040**
            \<3.4       189 (59.6%)           277 (48.2%)          **0.0011**
            ≧3.4        128 (40.4%)           298 (51.8%)          

The 5-year OS of patients with stage II and III CRC were 85.1% and 72.0%, respectively. Univariate analysis showed that age, sex, stage, CRP, lymphocyte (%), monocyte (%), RBC count, Hb, MCV, RDW, platelet count, NLR, LMR, CONUT, and Onodera PNI were significantly correlated with OS ([Table 4](#pone.0220579.t004){ref-type="table"}). The multivariate analysis showed that sex, stage, RBC count, and RDW were significantly correlated with OS.

10.1371/journal.pone.0220579.t004

###### Univariate and multivariate analyses of clinical and pathological parameters for the prediction of overall survival.
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                                                                                                Univariate analysis   Multivariate analysis                           
  ------------------------------------- ---------------------------------------- -------- ----- --------------------- ----------------------- ----------------------- --------------
  Age                                   \<65                                              271   82.9%                 **0.0213**              1                       0.0891
                                        ≧65                                               621   76.7%                 1.35 (0.95--1.97)                               
  Sex                                   Male                                              511   75.8%                 **0.0019**              **1.58 (1.14--2.20)**   **0.0058**
                                        Female                                            381   82.3%                 1                                               
  Tumor location                        Right sided colon                                 317   79%                   0.2737                                          
                                        Left side colon                                   299   81.2%                                                                 
                                        Rectum                                            276   74.9%                                                                 
  Histological grade                    well differentiated                               59    77.7%                 0.5451                                          
                                        moderately differentiated                         766   79.1%                                                                 
                                        poorly differentiated                             12    60.6%                                                                 
                                        other                                             55    76.9%                                                                 
  Stage                                 II                                                448   85.1%                 **\<0.0001**            1                       **\<0.0001**
                                        III                                               444   72.0%                 **2.00 (1.46--2.77)**                           
  Laboratory Data                       C-reactive protein (mg/dL)               \<0.5    424   79.9%                 **0.0353**              1                       0.3984
                                                                                 ≧0.5     249   73.0%                 1.15 (0.83--1.60)                               
                                        Albumin (g/dL)                           \<2.7    36    70.7%                 0.1001                                          
                                                                                 ≧2.7     856   79.0%                                                                 
                                        Total cholesterol (mg/dL)                \<220    758   77.6%                 0.1096                                          
                                                                                 ≧220     134   84.0%                                                                 
                                        White blood cell count (x10^9^/L)        \<5.50   325   81.3%                 0.1030                                          
                                                                                 ≧5.50    567   77.0%                                                                 
                                        Neutrophil (%)                           \<73.7   751   79.2%                 0.0728                                          
                                                                                 ≧73.7    141   75.6%                                                                 
                                        Lymphocyte (%)                           \<14.9   111   71.4%                 **0.0094**                                      
                                                                                 ≧14.9    781   79.6%                                                                 
                                        Monocyte (%)                             \<8.0    540   82.6%                 **0.0011**                                      
                                                                                 ≧8.0     352   72.4%                                                                 
                                        Red blood cell count (x10^9^/μL)         \<3.53   187   68.7%                 **\<0.0001**            **1.80 (1.24--2.59)**   **0.0024**
                                                                                 ≧3.53    705   81.4%                 1                                               
                                        Hemoglobin (g/dL)                        \<9.5    154   77.4%                 0.8685                                          
                                                                                 ≧9.5     738   78.9%                                                                 
                                        Mean corpuscular volume (MCV) (fl)       \<80.5   160   86.6%                 **0.0019**              1.40 (0.85--2.41)       0.1830
                                                                                 ≧80.5    732   76.9%                 1                                               
                                        Red cell distribution width (RDW)        \<18.5   680   77.9%                 **0.0408**              1                       **0.0477**
                                                                                 ≧18.5    212   81.0%                 **1.56 (1.00--2.49)**                           
                                        Platelets count (x10^9^/L)               \<364    746   77.3%                 **0.0386**                                      
                                                                                 ≧364     146   85.5%                                                                 
                                        Neutrophil-to-lymphocyte ratio (NLR)     \<5.5    801   79.8%                 **0.0069**              1.35(0.84--2.11)        0.2062
                                                                                 ≧5.5     91    68.1%                 1                                               
                                        Lymphocyte-to- monocyte ratio (LMR)      \<3.4    466   74.4%                 **0.0010**              1.30 (0.91--1.86)       0.1495
                                                                                 ≧3.4     426   83.0%                 1                                               
                                        Platelets-to-lymphocyte ratio (PLR)      \<218    607   79.2%                 0.5393                                          
                                                                                 ≧218     285   77.2%                                                                 
                                        Glasgow prognostic score (GPS)           0        404   79.6%                 0.1788                                          
                                                                                 1--2     269   73.8%                                                                 
                                        Controlling nutritional status (CONUT)   0--4     741   80.7%                 **0.0003**              1                       0.6614
                                                                                 5--12    151   67.4%                 1.13 (0.66--1.94)                               
                                        Onodera PNI                              \<41.8   252   69.2%                 **0.0002**              1.10 (0.67--1.74)       0.7026
                                                                                 ≧41.8    640   82.0%                 1                                               
  Postoperative adjuvant chemotherapy   done                                              271   78.6%                 0.6399                                          
                                        not done                                          621   78.7%                                                                 

The RFS and OS of the study patients were well stratified by an LPS between 0 and 6 ([Fig 1](#pone.0220579.g001){ref-type="fig"}). The RFS and OS of stage II and III CRC patients were significantly inferior with an LPS of 4--6 than with an LPS of 0--3 ([Fig 2](#pone.0220579.g002){ref-type="fig"}). Additional subgroup analysis based on PAC was performed (Fig [3A and 3B](#pone.0220579.g003){ref-type="fig"}). Although the RFS of the patients who did not receive PAC was significantly stratified by the LPS, prognostication by LPS was less remarkable in patients who received PAC. The RFS of stage II CRC patients who received PAC was inferior to that of patients who did not receive PAC, regardless of the LPS. On the other hand, for the stage III CRC patients with an LPS of 4--6, the 5-year RFS tended to be better in those who received PAC than in those who did not receive PAC (63.8% vs. 53.6%, p = 0.0665).

![Outcomes of all patients based on laboratory prognostic score (LPS): The RFS (a) and OS (b) curves. **The RFS(a) and OS (b) were well stratified by LPS**.](pone.0220579.g001){#pone.0220579.g001}

![Outcomes of all patients according to stage and laboratory prognostic score (LPS): RFS (a) and OS (b) curves. **The RFS (a) and OS (b) classified by stage and LPS were well stratified by LPS in stage II and III**.](pone.0220579.g002){#pone.0220579.g002}

![RFS curves according to stage and LPS: (a) patients without postoperative adjuvant chemotherapy (PAC), (b) patients with PAC. **The RFS of patients who did not receive PAC was significantly stratified by LPS of 0--3 and 4--6 (Fig 3A); however, the prognostication by LPS was less remarkable in patients who received PAC (Fig 3B)**.](pone.0220579.g003){#pone.0220579.g003}

Discussion {#sec011}
==========

Our findings demonstrated that preoperative MCV ≥ 80.5 fL, NLR ≥ 5.5, and LMR \< 3.4 were significant predictors of poor RFS in stage II and III CRC patients who underwent curative resection. The RFS and OS of stage II and III patients were significantly stratified by the LPS, which was developed from the three indices.

The MCV indicates the volume of RBCs and is frequently used for the diagnosis of megaloblastic or iron-deficiency anemia. Meanwhile, recent studies found a prognostic implication of MCV in esophageal and liver cancer \[[@pone.0220579.ref019]--[@pone.0220579.ref021]\]. Our group previously reported that MCV was a prognostic factor for RFS in patients who underwent R0 resection for stage I/II/III CRC, independent of the tumor stage \[[@pone.0220579.ref022]\]; a low MCV or microcytosis (MCV \< 80 fL) was associated with favorable outcomes. Schneider C et al. reported that Hb and MCV dropped shortly before the CRC diagnosis, and low MCV was weakly associated with survival of patients with CRC \[[@pone.0220579.ref023]\]. CRC is often accompanied by iron-deficiency anemia, which leads to decreased MCV. The mechanism responsible for the association between MCV and disease relapse is unknown, although several hypotheses have been proposed. First, oxidative stress had been implicated in a variety of chronic diseases, and the antioxidant capacity of the body had been related with the size of the circulating RBCs \[[@pone.0220579.ref024]\]. Because an elevated MCV or macrocytosis may reflect structural or functional disorders of RBCs, its unfavorable effects on relapse after R0 resection for CRC can be explained by a disturbed antioxidant capacity. Additionally, impaired deformability of the RBCs from high oxidative stress can damage the microcirculation and oxygen delivery to tissues \[[@pone.0220579.ref025], [@pone.0220579.ref026]\]. Second, macrocytosis may be a sign of disturbed hematopoiesis due to bone marrow dysfunction. Bone marrow-derived mesenchymal stem cells have been reported to play a critical role in the repair of several damaged vital organs \[[@pone.0220579.ref027]\]. Mahmoud et al. reported that unexplained macrocytosis in elderly patients was related with dysplastic or pathologic findings consistent with myelodysplastic syndrome \[[@pone.0220579.ref028]\]. Ueda et al. investigated the blood cell components in patients with acute decompensated heart failure and showed that the WBC and platelet counts were significantly lower in the macrocytic group than in the non-macrocytic group \[[@pone.0220579.ref029]\]. Third, although our study showed that albumin, T-Chol, GPS, CONUT score, and Onodera's PNI were not significantly associated with RFS, the patients' nutrition can be related with MCV. A relatively high MCV may be a surrogate marker of folic acid or vitamin B12 deficiency, which the present study did not investigate. Fourth, crystal osmotic pressure, which is closely related with MCV and is mainly determined by the serum concentrations of glucose, amino acids, and electrolytes, regulates the RBC size \[[@pone.0220579.ref030]\]. These factors that can affect RBC volume were not investigated in the present study. Fifth, tumor location can be related with MCV. Väyrynen et al. reported that proximal tumor location was associated with predominant microcytic anemia \[[@pone.0220579.ref031]\]. Several studies showed that the prognosis of patients who underwent curative resection for RCRC was favorable, compared with that for LCRC \[[@pone.0220579.ref032]--[@pone.0220579.ref034]\]. Our study showed that the proportion of MCV\<80.5 fL in patients with RCRC was significantly higher than those with LCRC, however, MCV was remained as a prognostic factor in a subgroup analysis of the tumor location. Sixth, endothelial function can be related with MCV. Endothelial dysfunction had been considered as one of the important mechanisms of the association between cardiovascular disease and chronic kidney disease \[[@pone.0220579.ref035]\]. Flow-mediated dilation, which is a noninvasive examination to assess vascular function, was demonstrated by Solak et al. to have an inverse association with MCV, independent of insulin resistance and inflammation \[[@pone.0220579.ref036]\].

The present study showed that the NLR was the second important prognostic factor among the blood cell markers. Tumor-associated inflammatory cytokines and mediators may mediate inflammatory responses, which lead to tumor growth, infiltration, and metastasis. Lymphopenia is a surrogate marker for impaired cell-mediated immunity, whereas neutrophilia is acknowledged as a response to systematic inflammation \[[@pone.0220579.ref037]\]. Lymphocytes participate in cytotoxic cell death and inhibition of tumor cell proliferation and migration \[[@pone.0220579.ref038], [@pone.0220579.ref039]\]. The NLR, which is equivalent to the number of neutrophils divided by the number of lymphocytes, had been widely investigated as an indicator of systemic inflammatory response in CRC. Many studies showed that a high NLR, with cutoff values ranging between 2 and 5, was associated with poor long-term outcomes in patients with CRC \[[@pone.0220579.ref002], [@pone.0220579.ref005], [@pone.0220579.ref009], [@pone.0220579.ref040]--[@pone.0220579.ref045]\].

Monocytes can promote tumor progression and metastasis \[[@pone.0220579.ref046], [@pone.0220579.ref047]\]. Tumor-associated macrophages (TAM) that are derived from circulating monocytes can suppress adaptive immunity and promote angiogenesis, invasion, and migration \[[@pone.0220579.ref048]\]. Increased circulating monocytes may reflect increased levels of TAM and worse prognosis. However, the circulating monocyte level had not been widely investigated as a biomarker of CRC. The LMR is the ratio of the absolute lymphocyte count to the absolute monocyte count in blood. Stotz et al. showed the prognostic value of preoperative LMR (2.83) in patients with stage III CRC \[[@pone.0220579.ref049]\], and was in line with the results of studies by Song Y et al \[[@pone.0220579.ref002]\] and Chan JC et al \[[@pone.0220579.ref012]\]. Recent studies have indicated that low LMR, with cutoff values ranging between 3.0 and 4.8, was associated with poor long-term outcomes in patients with CRC \[[@pone.0220579.ref002], [@pone.0220579.ref012], [@pone.0220579.ref049]--[@pone.0220579.ref053]\].

The present study revealed that MCV, NLR, and LMR were superior to the conventional blood markers, including CRP, albumin, T-Chol, GPS, CONUT score, and Onodera's PNI \[[@pone.0220579.ref007], [@pone.0220579.ref014], [@pone.0220579.ref015]\], in predicting RFS. This result suggested that these conventional prognostic markers were less useful for the prognostication of patients who underwent R0 resection for stage II and III CRC. Chan JC et al. reported similar results of ours about GPS \[[@pone.0220579.ref012]\]. The discrepancy among the studies may be derived from the differences in patient selection, tumor stage, treatment, and outcomes measurement.

We developed the LPS for easy application of these three indices (i.e., MCV ≥ 80.5 fL, NLR ≥ 5.5, and LMR \< 3.4) for prognostication. The RFS of stage II and III CRC patients was significantly inferior with an LPS of 4--6 than with an LPS of 0--3 ([Fig 2](#pone.0220579.g002){ref-type="fig"}). Additional subgroup analysis according to PAC showed that the RFS of patients who did not receive PAC was significantly stratified by LPS of 0--3 and 4--6 ([Fig 3A](#pone.0220579.g003){ref-type="fig"}); however, the prognostication by LPS was less remarkable in patients who received PAC ([Fig 3B](#pone.0220579.g003){ref-type="fig"}). The RFS of stage II CRC patients who received PAC was inferior to those who did not receive PAC, regardless of the LPS. This can be partly explained by the fact that the stage II CRC patients who received PAC had several poor prognostic factors. On the other hand, the 5-year RFS of stage III CRC patients with an LPS of 4--6 tended to be better in those who received PAC than in those who did not receive PAC (p = 0.065). The result suggested the protective effect of PAC in patients with LPS 4--6 and the usefulness of LPS in predicting the response to PAC in stage III CRC.

The current study had several limitations. First, it was a retrospective single-institutional study, although it included a large and homogenous dataset. The unknown backgrounds that may affect MCV, lymphocytes, and monocytes may have led to a selection bias. Second, patients who received PAC were included and comprised 30% of the entire cohort. PAC modifies the RFS and can act as an important confounder. Patient choice, age, comorbidities, and postoperative complications can affect the performance of PAC. Nevertheless, our additional subgroup analysis based on PAC showed that the RFS of the patients who did not receive PAC was significantly different between LPS 0--3 and 4--6. Third, the patients' performance status (e.g., the American Society of Anesthesiologists score), surgical approach (open or laparoscopic), and postoperative complications, all of which can affect the RFS, were not investigated in this study. Fourth, CRP was measured in only 75% of the entire cohort, because our surgical department did not have routine preoperative measurement of CRP. Comparison of the prognostic ability among MCV, NLR, LMR, and GPS will be necessary in future studies with full measurement. Despite these limitations, the results of our study may be clinically relevant in the context of pre- and postoperative treatment or surveillance planning, because MCV, NLR, and LMR can be obtained from routine blood cell examination, which is readily available and inexpensive.

Conclusions {#sec012}
===========

MCV, NLR, and LMR were useful blood cell markers that significantly predicted the RFS of patients who underwent R0 resection for stage II and III CRC, independent of tumor stage. The LPS developed from these three factors can predict response to PAC in stage III CRC. Future prospective studies are required to validate these results.
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